The case for & against
Bull & Bear analysis
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders, focusing particularly on ADHD and Parkinson's disease treatments. Over recent years, the company has positioned itself for strong growth through product diversification and strategic acquisitions, including the purchase of Sage Therapeutics. With strong recent product launches and a promising pipeline, Supernus is entering an exciting phase centered around neuroscience medications, making it an emerging player in the psychiatric pharmaceutical space.
Bull says
- ↑39% YoY revenue growth to $207.7M in Q1 2026
- ↑Ongoing trials for SPN-820 & SPN-817 with FDA submission due
- ↑$384M cash balance and zero debt fund R&D and acquisitions
- ↑Shares rallied 5.2% post-earnings, reflecting investor confidence
- ↑High earnings yield, strong growth momentum and low leverage risk
Bear says
- ↓Q1 operating loss of $8.3M highlights profitability struggles
- ↓High SG&A and integration costs pressure margins
- ↓Only 29K Zerzuve patients treated despite 82% Rx growth
- ↓Reliance on few key drugs raises revenue concentration risk
- ↓Q2 EPS estimate $0.55, 39.6% YoY decline signals earnings risk
- ↓Low dividend yield, weak institutional ownership and negative revisions
Investment themes with SUPN
Drug development driving global healthcare solutions
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We achieved total revenue of $207.7 million for the first quarter of 2026, an increase of 39% compared to the same quarter last year.
- Total revenues were comprised of revenues from our commercial products, including Zerjuve, collaboration revenues, and royalty, licensing, and other revenues.
- Revenues from commercial products increased to $178 million, a 26% increase compared to the same quarter last year, primarily due to the increase in net sales of our growth products, Calgary, GoCoverry, and Enabco, as well as the addition of collaboration revenues from Zerzune.
Bear points
- For the first quarter of 2026, combined R&D and SG&A expenses were $164.6 million as compared to $116.9 million for the same quarter last year, primarily due to an increase in SG&A expenses associated with the collaboration agreement with Biogen.
- Operating loss on a GAAP basis for the first quarter of 2026 was $8.3 million, compared to an operating loss of $10.3 million for the same quarter last year, indicating significant operational challenges despite higher revenues.
- it's a little bit too early for us to evaluate patient persistence for Bonapco due to the disruption in supply. We are watching it very carefully, and we do have dropouts that are fairly consistent with the clinical study, maybe a little bit more.